News

Biopharma news, November 9, 2026

The most important drug and company news of November 9, 2026, ranked, each linked to its Gosset profiles.

  1. M&A

    Mentari closes InMed merger and $490 million financing, lists on Nasdaq as MTRI

    Migraine-prevention developer Mentari Therapeutics has finished combining with InMed Pharmaceuticals and started trading under the ticker MTRI. Its $490 million in private financing, which includes $50 million of converted notes, is expected to fund operations into 2029. First Phase 1 data for MT-001 are due in mid-2027, and MT-002 is set for a regulatory filing in early 2027.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  2. Approval

    Brazil clears Henlius' HLX11, its first pertuzumab biosimilar, for HER2+ breast cancer

    Anvisa approved HLX11 in combination regimens for metastatic or unresectable locally recurrent HER2-positive breast cancer and for eligible patients before or after surgery. The decision drew on analytical and pharmacokinetic work plus a comparative clinical study. Henlius developed the biosimilar, and Organon holds commercial rights outside China.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  3. Pivotal readout

    Innovent's tafolecimab lowers LDL-C about 65% as first-line monotherapy in Phase 3

    In the 198-patient CREDIT-5 trial, Sintbilo given alone as first-line therapy met its week-12 primary endpoint, cutting LDL cholesterol by roughly 64% to 65%. No serious or severe adverse events, and none leading to discontinuation, were reported. Innovent plans to file the new indication with China's drug regulator soon.

    Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

  4. Pivotal readout

    UCB's bimekizumab keeps its edge over risankizumab in psoriatic arthritis at week 24

    In BE BOLD, a Phase 3b head-to-head study, 54.9% of patients on Bimzelx reached ACR50 at week 24, compared with 43.8% on Skyrizi, extending the superiority shown at week 16. The top-ranked secondary endpoint missed significance, and complete skin clearance was about equal. Localized Candida infections were more common with Bimzelx, and full results go to ACR Convergence.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  5. Approval

    Beijing Fuyuan gets Chinese nod for generic extended-release upadacitinib

    China cleared Beijing Fuyuan Pharmaceutical's copy of upadacitinib, and the approval counts as passing the generic consistency evaluation. Upadacitinib sales in tracked Chinese markets neared RMB 1 billion in 2025 after 81.74% growth, so generic entry is getting crowded. Fuyuan has now logged 23 product approvals this year and spent about RMB 8.54 million developing this one.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  6. Pivotal readout

    Roche's satralizumab keeps most thyroid eye disease responders through week 48

    Pooled 48-week data from two Phase 3 studies, SatraGO-1 and SatraGO-2, show that about 85% of week-24 responders on satralizumab (Enspryng) were still responding at week 48. Safety data raised no new concerns and showed no serious infections. The IL-6 receptor antibody won US approval for adults with thyroid eye disease last month and has been filed in China.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  7. Approval

    Kanghong Pharmaceutical gets Chinese marketing approval for ibrutinib capsules

    China's drug regulator issued Chengdu Kanghong Pharmaceutical Group a registration certificate for ibrutinib capsules, a BTK inhibitor. The listed uses include mantle cell lymphoma, CLL/SLL and Waldenström's macroglobulinemia. The company says the product adds to its cancer portfolio.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  8. Approval

    Israel approves ImmunityBio's ANKTIVA with BCG for BCG-unresponsive bladder cancer

    Israel's health ministry cleared ANKTIVA, given together with BCG, for adults whose non-muscle-invasive bladder tumours include carcinoma in situ and no longer respond to BCG. The review took four months, and the formal registration license should follow within weeks. Rafa Laboratories will sell the drug in Israel, and the companies count 35 countries where ANKTIVA is now authorized.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  9. M&A

    CorMedix agrees to buy almost all Heron assets, adding four marketed drugs

    CorMedix will pay $145 million in cash plus 14,583,333 of its shares for Heron's ZYNRELEF, APONVIE, CINVANTI and SUSTOL. Heron could also earn as much as $55 million tied to ZYNRELEF sales, plus a 5% royalty above a sales threshold. The deal needs Heron shareholder and antitrust approval and is slated to close in early 2027.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  10. M&A

    argenx to acquire peptide firm Unnatural Products in deal worth up to $1.15 billion

    argenx is buying its research partner of two years for $550 million upfront, gaining an AI-guided platform for discovering macrocyclic peptides. Milestone-linked payments could lift the total to about $1.15 billion. The Santa Cruz team will stay in place as argenx's peptide discovery hub, and closing is targeted for the end of the year.

    Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call